Actively Recruiting

Phase 4
Age: 18Years +
All Genders
ID07228221

iStent Infinite and iDose TR Surgery for Moderate to Severe Primary Open Angle Glaucoma as an Alternative to Filtering Surgery for Eye Pressure Reduction

Led by Jonathon Myers · Updated on 2025-11-14

20

Participants Needed

1

Research Sites

17 weeks

Total Duration

On this page

Sponsors

J

Jonathon Myers

Lead Sponsor

G

Glaukos Corporation

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the effectiveness of combining the minimally invasive iStent infinite trabecular micro-bypass system and the iDose TR (Travoprost intracameral Implant) in patients with moderate to severe open angle glaucoma that is not controlled by medication. This study aims to determine if this combination can serve as a safe and effective alternative to traditional filtering surgery for reducing intraocular pressure in these patients. The investigation focuses on measuring changes in eye pressure, medication use, additional surgeries, and adverse events. Participants will undergo surgery that uses the combined iStent infinite device and iDose TR drug implant to reduce eye pressure. This approach involves implanting both a micro-bypass stent and a drug depot into the eye during the procedure. The study does not include a comparison or placebo group; all participants will receive this combined treatment. Researchers will monitor participants over time to assess outcomes and safety. Throughout the study, participants will have their intraocular pressure measured, including diurnal pressure changes, and their use of glaucoma medications recorded. The need for further incisional glaucoma surgery and any side effects will also be tracked. Visual acuity and visual field measurements will be assessed to evaluate eye health. The main outcome is the reduction in intraocular pressure at 12 months compared to baseline. Participants' progress will be followed closely to ensure safety and effectiveness during the trial period.

CONDITIONS

Brief Title

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Moderate to severe open angle glaucoma including primary, pigmentary, and pseudoexfoliation types
  • Open angle configuration with Shaffer grade 3 or higher and normal angle anatomy
  • Visual acuity of hand motion or better
  • Visual field mean deviation of -6 dB or worse
  • Failed medical therapy and/or laser treatment
  • Incisional glaucoma surgery planned as the next step
  • Phakic or pseudophakic eye status
Not Eligible

You will not qualify if you...

  • Traumatic, uveitic, neovascular, or angle closure glaucoma
  • Previous incisional glaucoma surgery
  • Argon laser trabeculoplasty; history of iridotomy, selective laser trabeculoplasty, or micropulse laser trabeculoplasty within 90 days
  • Active eye inflammation or edema, significant corneal dystrophy
  • Corneal or other eye conditions preventing accurate Goldmann applanation tonometry

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Surgery and Immediate Post-operative Care

Duration - Day of surgery and immediate recovery period

Participants undergo combined minimally invasive surgery using the iStent infinite trabecular micro-bypass system and receive the iDose TR drug implant.

1 surgery visit and several immediate post-operative visits

Post-operative Follow-up

Duration - Up to 12 months

Participants are monitored for intraocular pressure changes, medication use, need for additional surgery, and adverse events following surgery.

Regular follow-up visits over 12 months

Trial Site Locations

Total: 1 location

1

Wills Eye Hosital Glaucoma Dept.

Philadelphia, Pennsylvania, United States, 19107

Actively Recruiting

Loading map...

Research Team

M

Meskerem Divers

J

Jeanne L Molineaux, COA

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

1

Similar Trials

24-hour Effect of Rocklatan Compared With Latanoprost in Ope...

Open Angle Glaucoma

Actively Recruiting

1 location

Safety and Effectiveness of ELIOS vs Competitor Device in Op...

Open Angle Glaucoma

Actively Recruiting

16 locations

Efficacy and Tolerability of Simbrinza and Rocklatan Compare...

Open Angle Glaucoma

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here